# Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

> **NCT00316875** · PHASE1 · COMPLETED · sponsor: **Northwestern University** · enrollment: 23 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** lapatinib ditosylate
- **DRUG:** Doxil

## Key facts

- **NCT ID:** NCT00316875
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2013-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316875, "Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00316875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*